Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Bortezomib in Low/Intermediate-1 Risk MDS
NCT01891968Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response at 8 weeks. Started Aug 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01891968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01891968.